Literature DB >> 2393292

Activities of (-)-carbovir and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro.

S G Carter1, J A Kessler, C D Rankin.   

Abstract

(-)-Carbovir, the minus optical isomer of carbocyclic-2',3'-didehydro-2',3'-dideoxyguanosine, has been shown to be the biologically active form for the inhibition of human immunodeficiency virus type 1 replication. The concentration of (-)-carbovir required to reduce reverse transcriptase activity by 50% compared with the control was 0.8 microM in H9 cells infected with the HTLV-IIIb strain; the 50% inhibitory concentration for cytotoxicity was greater than 2 mM in these cells. The effect of the timing of drug addition, pre- and postinfection, and the effect of increasing amounts of virus on the antiviral activities of (-)-carbovir and 3'-azido-3'-deoxythymidine were determined.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2393292      PMCID: PMC171808          DOI: 10.1128/AAC.34.6.1297

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Nucleotide sequence of the visna lentivirus: relationship to the AIDS virus.

Authors:  P Sonigo; M Alizon; K Staskus; D Klatzmann; S Cole; O Danos; E Retzel; P Tiollais; A Haase; S Wain-Hobson
Journal:  Cell       Date:  1985-08       Impact factor: 41.582

2.  Human T-cell lymphotropic virus type III shares sequence homology with a family of pathogenic lentiviruses.

Authors:  M A Gonda; M J Braun; J E Clements; J M Pyper; F Wong-Staal; R C Gallo; R V Gilden
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

3.  Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases.

Authors:  E L White; W B Parker; L J Macy; S C Shaddix; G McCaleb; J A Secrist; R Vince; W M Shannon
Journal:  Biochem Biophys Res Commun       Date:  1989-06-15       Impact factor: 3.575

4.  Azidothymidine neurotoxicity.

Authors:  D N Hagler; P T Frame
Journal:  Lancet       Date:  1986-12-13       Impact factor: 79.321

Review 5.  A pathogenic retrovirus (HTLV-III) linked to AIDS.

Authors:  S Broder; R C Gallo
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

6.  Pulmonary complications of the acquired immunodeficiency syndrome. Report of a National Heart, Lung, and Blood Institute workshop.

Authors:  J F Murray; C P Felton; S M Garay; M S Gottlieb; P C Hopewell; D E Stover; A S Teirstein
Journal:  N Engl J Med       Date:  1984-06-21       Impact factor: 91.245

7.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

8.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

9.  Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome.

Authors:  J L Ziegler; J A Beckstead; P A Volberding; D I Abrams; A M Levine; R J Lukes; P S Gill; R L Burkes; P R Meyer; C E Metroka
Journal:  N Engl J Med       Date:  1984-08-30       Impact factor: 91.245

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  7 in total

Review 1.  Antiretroviral therapy: reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro.

Authors:  J A Coates; N Cammack; H J Jenkinson; I M Mutton; B A Pearson; R Storer; J M Cameron; C R Penn
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

3.  Human immunodeficiency virus infection and syncytium formation in HeLa cells expressing glycophospholipid-anchored CD4.

Authors:  T A Kost; J A Kessler; I R Patel; J G Gray; L K Overton; S G Carter
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

4.  Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism.

Authors:  W B Parker; S C Shaddix; B J Bowdon; L M Rose; R Vince; W M Shannon; L L Bennett
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

Review 5.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

6.  Evaluation of synergy between carbovir and 3'-azido-2',3'-deoxythymidine for inhibition of human immunodeficiency virus type 1.

Authors:  M S Smith; J A Kessler; C D Rankin; J S Pagano; J Kurtzberg; S G Carter
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

Review 7.  The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold.

Authors:  Katherine L Seley-Radtke; Mary K Yates
Journal:  Antiviral Res       Date:  2018-04-10       Impact factor: 10.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.